Cefixime clinical studies: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Cefixime}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE ...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Clinical Studies== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE SUPRAX (CEFIXIME) TABLET, CHEWABLE SUPRAX (CEFIXIME) POWDER, FOR SUSPENSION [LUPIN PHARMA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2 |publisher = | date = | accessdate = }}</ref> | Comparative clinical trials of [[otitis media]] were conducted in nearly 400 children between the ages of 6 months to 10 years. Streptococcus pneumoniae was isolated from 47% of the patients, Haemophilus influenzae from 34%, Moraxella catarrhalis from 15% and S. pyogenes from 4%. | ||
The overall response rate of [[Streptococcus pneumoniae]] to cefixime was approximately 10% lower and that of [[Haemophilus]] influenzae or Moraxella catarrhalis approximately 7% higher (12% when beta-lactamase positive isolates of H. influenzae are included) than the response rates of these organisms to the active control drugs. | |||
In these studies, patients were randomized and treated with either cefixime at dose regimens of 4 mg/kg twice a day or 8 mg/kg once a day, or with a comparator. Sixty-nine to 70% of the patients in each group had resolution of signs and symptoms of otitis media when evaluated 2 to 4 weeks post-treatment, but persistent effusion was found in 15% of the patients. When evaluated at the completion of therapy, 17% of patients receiving cefixime and 14% of patients receiving effective comparative drugs (18% including those patients who had Haemophilus influenzae resistant to the control drug and who received the control antibiotic) were considered to be treatment failures. By the 2 to 4 week follow-up, a total of 30%-31% of patients had evidence of either treatment failure or recurrent disease.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SUPRAX (CEFIXIME) TABLET SUPRAX (CEFIXIME) CAPSULE SUPRAX (CEFIXIME) TABLET, CHEWABLE SUPRAX (CEFIXIME) POWDER, FOR SUSPENSION [LUPIN PHARMA] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d0fd45bd-7d52-4fa6-a5f7-f46d5651ffa2 |publisher = | date = | accessdate = }}</ref> | |||
{| | |||
|[[File:4weeksoutcomeafter therapycefixime.JPG|800px|thumb]] | |||
|} | |||
==References== | ==References== | ||
Latest revision as of 20:48, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Clinical Studies
Comparative clinical trials of otitis media were conducted in nearly 400 children between the ages of 6 months to 10 years. Streptococcus pneumoniae was isolated from 47% of the patients, Haemophilus influenzae from 34%, Moraxella catarrhalis from 15% and S. pyogenes from 4%.
The overall response rate of Streptococcus pneumoniae to cefixime was approximately 10% lower and that of Haemophilus influenzae or Moraxella catarrhalis approximately 7% higher (12% when beta-lactamase positive isolates of H. influenzae are included) than the response rates of these organisms to the active control drugs.
In these studies, patients were randomized and treated with either cefixime at dose regimens of 4 mg/kg twice a day or 8 mg/kg once a day, or with a comparator. Sixty-nine to 70% of the patients in each group had resolution of signs and symptoms of otitis media when evaluated 2 to 4 weeks post-treatment, but persistent effusion was found in 15% of the patients. When evaluated at the completion of therapy, 17% of patients receiving cefixime and 14% of patients receiving effective comparative drugs (18% including those patients who had Haemophilus influenzae resistant to the control drug and who received the control antibiotic) were considered to be treatment failures. By the 2 to 4 week follow-up, a total of 30%-31% of patients had evidence of either treatment failure or recurrent disease.[1]
 |
References
Adapted from the FDA Package Insert.